<DOC>
	<DOCNO>NCT00539695</DOCNO>
	<brief_summary>Patients ask participate study treatment disease require stem cell transplant ( SCT ) . Stem cell source normal blood cell find bone marrow lead recovery blood count bone marrow transplantation . With stem cell transplant , regardless whether donor full match patient , risk develop graft-versus-host disease ( GVHD ) . GVHD serious sometimes fatal side effect SCT . GVHD occur new donor stem cell ( graft ) recognize body tissue patient ( host ) different donor . When happen , cell graft may attack host organ . How much happen severe GVHD depend many thing , include different donor cell , strength drug give preparation transplant , quality transplant cell age person receive transplant . Typically , acute GVHD occur first 100 day follow transplant , chronic GVHD occur day 100 . Acute GVHD often involve skin , cause anywhere mild rash complete removal skin ; liver , anywhere rise liver function test liver failure ; gut , cause anywhere mild diarrhea profuse , life-threatening diarrhea . Most patient develop GVHD experience mild moderate form , patient develop severe , life-threatening form . Previous study show patient receive SCT 's low number special T cell blood , call regulatory T cell , people receive stem cell transplant . When regulatory T cell low , appear increased rate severe , acute GVHD . A drug know IL-2 ( Proleukin ) show increase number regulatory T cell patient follow stem cell transplant , study investigator plan give low dose IL-2 transplant . This study call phase II study major purpose find whether use low-dose IL-2 effective prevent acute GVHD . Other important purpose find treatment help patient 's immune system recover regulatory T cell faster transplant . This study ass safety toxicity low-dose IL-2 give patient transplantation determine whether drug helpful prevent GVHD .</brief_summary>
	<brief_title>Low Dose IL-2 , Hematopoietic Stem Cell Transplantation , IL2 GVHD</brief_title>
	<detailed_description>Participation protocol last 1 year . To participate study , patient need undergone stem cell transplant . Before treatment start , investigator would like test patient 's blood blood number regulatory T cell already present begin IL-2 . Treatment Plan : Before condition treatment transplant , 30 40 ml ( 6 8 teaspoonful ) blood collect patient regulatory T cell analysis . Approximately amount blood also collect day 0 ( day transplant ) , follow time transplant : day 7 ( day IL-2 likely start ) weekly another eleven week , monthly 8 month . On approximately day 7 follow transplant , patient well meet eligibility requirement , IL-2 injection begin . These give subcutaneously ( small injection skin ) three time per week 6 week . The injection may also give special catheter , call Insuflon catheter , place skin week time . The first dose must give hospital , remain dos give home . The patient taught give injection him/ . If patient 's body serious toxicity IL-2 develop severe GVHD , patient continue get injection way additional 6 week . If time patient develops severe GVHD serious toxicity relate IL-2 , injection stop . If patient 's disease return ( relapse ) engraft ( accept donor graft ) , patient remove study . The patient 's lab follow closely he/she receive IL-2 injection , well heart , kidney lung function ; however , standard test patient receive transplant regardless participation study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>INCLUSION CRITERIA : INCLUSION CRITERIA FOR INITIAL STUDY ENROLLMENT : Patients eligible initial enrollment study long meet follow criterion : Diagnosis acute lymphoblastic leukemia , acute myelogenous leukemia , chronic myelogenous leukemia , myelodysplastic syndrome , myeloproliferative disorder , Hodgkin lymphoma , nonHodgkin lymphoma nonmalignant disease require allogeneic HSCT Birth age 70 year age Study entry consent sign faxed Research Coordinator INCLUSION CRITERIA AT TIME OF IL2 ADMINISTRATION : At least day +7 post transplant Less equal 30 day post transplant Lansky Karnofsky score great equal 50 % Total bilirubin less equal 1.5mg/dL Alanine aminotransferase level ( ALT ) less equal five time normal , serum direct bilirubin less equal 1.5mg/dL , albumin great equal 3.0gm/dL Serum creatinine less three time normal creatinine clearance great 80mg/min/1.73m2 Ensure inform consent sign faxed Research Coordinator EXCLUSION CRITERIA : EXCLUSION CRITERIA AT TIME OF IL2 ADMINISTRATION : Patients ineligible receive IL2 injection follow true : Active , acute GVHD great equal grade II Serious , active bacterial , fungal viral infection ( i.e . intensive care ) Clinical Signs severe pulmonary dysfunction Clinical Signs sever cardiac dysfunction Receiving corticosteroid GVHD treatment Hypersensitivity allergy IL2</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Stem Cell transplant</keyword>
	<keyword>Graft verus host disease</keyword>
	<keyword>IL-2</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>acute myelogenous leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>myeloproliferative disorder</keyword>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>non-Hodgkin lymphoma</keyword>
	<keyword>non-malignant disease require allogeneic HSCT</keyword>
</DOC>